Phase 1, Open Label, Sequential Cohort, Dose Escalation Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumours.

Trial Profile

Phase 1, Open Label, Sequential Cohort, Dose Escalation Study of CP-751,871 in Combination With Sunitinib in Patients With Advanced Solid Tumours.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2014

At a glance

  • Drugs Figitumumab (Primary) ; Sunitinib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 09 May 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Apr 2013 Planned end date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 15 Mar 2013 Planned end date changed from 1 Feb 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top